Zepbound, Eli Lilly

Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for Self-Pay Patients
Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.
Eli Lilly and Company (LLY): Jim Cramer Sees a ‘Big Moat’ with Weight Loss Drug
We recently published a list of Jim Cramer Discusses These 13 Stocks & Criticizes Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other stocks that Jim Cramer discusses.
Eli Lilly cuts prices for Zepbound weight-loss drug again
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.
Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices
Eli Lilly said it has launched new doses of its obesity treatment drug and reduced its prices.
Eli Lilly is offering weight loss drug Zepbound at lower prices
Eli Lilly is lowering the cost barrier to its weight loss drug Zepbound. For many consumers, their insurance denies them coverage for weight loss drugs
Lilly offers weight-loss drugs in vials at a discount to fight competition
Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition from compounding pharmacies and rival Novo Nordisk .
Weight-loss drug battle: Who are the latest players involved
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly diving into the opportunity to make anti-obesity products. This article looks into key players in the arena.
Popular weight-loss drugs get cheaper: Novo Nordisk and Eli Lilly cut prices
Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of $499 takes effect immediately.
US judge denies injunction, restricting copies of Lilly weight-loss drug
A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and diabetes drugs Zepbound and Mounjaro in the United States.
Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs
A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs.
Compounders must stop making copies of Eli Lilly’s weight loss drugs: Judge
Compounders had been allowed to produce and sell hundreds of thousands of their own versions of popular anti-obesity drugs.
InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...